Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析

◆英語タイトル:Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15440
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Glenmark Pharmaceuticals Ltd (GLENMARK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company’s formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Mar 06,2019 Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15,2019 Glenmark Pharmaceuticals to establish new company in US
Feb 14,2019 Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19,2018 Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Glenmark Pharmaceuticals Ltd – Key Facts
Glenmark Pharmaceuticals Ltd – Key Employees
Glenmark Pharmaceuticals Ltd – Key Employee Biographies
Glenmark Pharmaceuticals Ltd – Major Products and Services
Glenmark Pharmaceuticals Ltd – History
Glenmark Pharmaceuticals Ltd – Company Statement
Glenmark Pharmaceuticals Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Glenmark Pharmaceuticals Ltd – Business Description
Product Category: Other Operating Revenue
Performance
Product Category: Sale of Products
Performance
Product Category: Sale of Services
Performance
Geographical Segment: Europe
Performance
Geographical Segment: India
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World (ROW)
Performance
Geographical Segment: USA
Performance
R&D Overview
Glenmark Pharmaceuticals Ltd – Corporate Strategy
Glenmark Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
Glenmark Pharmaceuticals Ltd – Strengths
Glenmark Pharmaceuticals Ltd – Weaknesses
Glenmark Pharmaceuticals Ltd – Opportunities
Glenmark Pharmaceuticals Ltd – Threats
Glenmark Pharmaceuticals Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15, 2019: Glenmark Pharmaceuticals to establish new company in US
Feb 14, 2019: Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19, 2018: Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States
Nov 13, 2018: Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018–19
Nov 07, 2018: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Oct 30, 2018: Glenmark Pharmaceuticals celebrates the inauguration of its U.S. manufacturing site in Monroe, North Carolina
Oct 18, 2018: Data on Glenmark Pharmaceuticals” GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Glenmark Pharmaceuticals Ltd, Key Facts
Glenmark Pharmaceuticals Ltd, Key Employees
Glenmark Pharmaceuticals Ltd, Key Employee Biographies
Glenmark Pharmaceuticals Ltd, Major Products and Services
Glenmark Pharmaceuticals Ltd, History
Glenmark Pharmaceuticals Ltd, Other Locations
Glenmark Pharmaceuticals Ltd, Subsidiaries
Glenmark Pharmaceuticals Ltd, Key Competitors
Glenmark Pharmaceuticals Ltd, Ratios based on current share price
Glenmark Pharmaceuticals Ltd, Annual Ratios
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
Glenmark Pharmaceuticals Ltd, Interim Ratios
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Glenmark Pharmaceuticals Ltd, Performance Chart (2014 - 2018)
Glenmark Pharmaceuticals Ltd, Ratio Charts
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Koninklijke Ahold Delhaize N.V.:戦略・SWOT・企業財務分析
    Koninklijke Ahold Delhaize N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Ahold Delhaize N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Fraser and Neave, Limited:企業の戦略・SWOT・財務情報
    Fraser and Neave, Limited - Strategy, SWOT and Corporate Finance Report Summary Fraser and Neave, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Dana Inc:企業の戦略・SWOT・財務分析
    Dana Inc - Strategy, SWOT and Corporate Finance Report Summary Dana Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • CESC Limited:企業の戦略・SWOT・財務分析
    CESC Limited - Strategy, SWOT and Corporate Finance Report Summary CESC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • International Data Group:戦略・SWOT・企業財務分析
    International Data Group - Strategy, SWOT and Corporate Finance Report Summary International Data Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • OBB-Infrastruktur AG:企業の戦略的SWOT分析
    OBB-Infrastruktur AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • DSE, Inc.:企業の戦略・SWOT・財務分析
    DSE, Inc. - Strategy, SWOT and Corporate Finance Report Summary DSE, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Aptiv PLC:企業の戦略・SWOT・財務情報
    Aptiv PLC - Strategy, SWOT and Corporate Finance Report Summary Aptiv PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • HLS Therapeutics Inc (HLS):製薬・医療:M&Aディール及び事業提携情報
    Summary HLS Therapeutics Inc (HLS Therapeutics) is a pharmaceutical company that offers central nervous system and cardiovascular therapeutic products. The company's product includes clozaril, absorica, vascepa and trinomial. Its clozapine is a pharmaceutical product used in the treatment of schizop …
  • China Longyuan Power Group Corp Ltd (916):企業の財務・戦略的SWOT分析
    China Longyuan Power Group Corp Ltd (916) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Ramsay Health Care Ltd (RHC):製薬・医療:M&Aディール及び事業提携情報
    Summary Ramsay Health Care Ltd (RHC) is a global healthcare group that owns and operates through healthcare facilities. Its facilities cater for a range of health care needs from day surgery procedures to complex surgeries. The company also provides psychiatric care and rehabilitation services. RHC …
  • Andhra Petrochemicals Ltd (500012):企業の財務・戦略的SWOT分析
    Andhra Petrochemicals Ltd (500012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • 3W Power S.A. (3W9K):電力:M&Aディール及び事業提携情報
    Summary 3W Power S.A. (3W Power) is a provider of energy equipment and services. It offers power supply systems and solutions. The company provides the most comprehensive product and service portfolios in uninterruptible power supply and power management fields. 3W Power offers a range of services s …
  • Ilyushin Aviation Complex OJSC:企業の戦略・SWOT・財務情報
    Ilyushin Aviation Complex OJSC - Strategy, SWOT and Corporate Finance Report Summary Ilyushin Aviation Complex OJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Merck & Co., Inc.:企業の戦略・SWOT・財務情報
    Merck & Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Merck & Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ZIOPHARM Oncology Inc (ZIOP):企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • Coca-Cola Amatil Limited:企業の戦略・SWOT・財務情報
    Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Frontera Energy Corp (FEC):企業の財務・戦略的SWOT分析
    Frontera Energy Corp (FEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Harry Ramsden’s:企業の戦略・SWOT・財務分析
    Harry Ramsden's - Strategy, SWOT and Corporate Finance Report Summary Harry Ramsden's - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • NuVasive Inc (NUVA):企業の製品パイプライン分析2018
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆